Apple and OpenEvidence open a 200,000-person health chatbot study: wearable and lab data in, no model training, no device claim. What health systems should watch
Apple has chosen the clinical search tool most US doctors already use as the engine for its first consumer health conversation, and is running it as research so it can learn what builds trust before it ships a product.

Apple used the HLTH conference in Las Vegas on Sunday to announce a virtual research study, delivered through a new app, built on OpenEvidence's clinical AI. Up to 200,000 US residents aged 21 and over can enrol. They can ask health questions, explore medical information, and optionally share data such as resting heart rate, activity, sleep and lab results so answers are personalised. Apple says participation and data sharing are opt-in and that study data will not be used to train AI models.
What Apple is testing
Sumbul Desai, Apple's vice president of health and fitness, described the research questions plainly: what builds user trust, how people comprehend responses, the quality of those responses, and whether a conversational system can change behaviour. The app can detect worrying questions and steer users toward an outside provider or other resources. OpenEvidence's chief executive, Daniel Nadler, framed the consumer use case as preparing for a 10- to 15-minute appointment: arrive with your data and your questions organised.
This is Apple's second large virtual study, after the 2025 Apple Health Study with Brigham and Women's Hospital that examines how its devices affect outcomes. The difference is that this one is built around a language model and a partner's brand.
Why OpenEvidence
OpenEvidence sells a medical search and answer engine to clinicians, free to use, and told NBC News earlier this year that almost two-thirds of US physicians use it. Desai said Apple wanted "a clinically grounded partner." The choice tells you what Apple thinks the risk is. General-purpose chatbots answer health questions fluently and sometimes wrongly; about a third of US adults have used one for health information, according to KFF, and the incomplete-answer problem is well documented. A model whose outputs are tied to the medical literature, and whose users are already doctors, is a defensible foundation for a consumer product that has not yet been built.
For OpenEvidence the deal is a route to the public. It has grown by giving physicians a free tool; a consumer channel attached to the most trusted hardware brand in health is the first visible step toward a business beyond pharmaceutical advertising to clinicians.
The regulatory shape
Neither company has called the app a medical device. Running it as a research study with informed consent is the way to collect evidence on quality, comprehension and behaviour change, which is exactly what a future FDA submission or a decision not to make one would rest on. The FDA's current thinking on generative AI in devices, consulted on through the autumn, turns on whether software makes or drives clinical decisions; an app that helps a person prepare questions for their doctor sits on the safer side of that line, and the study design keeps it there while the data accumulates.
The counter-argument
Two concerns stand. First, scale: a 200,000-person cohort sharing wearable and lab data with a third-party model is one of the larger consumer health-data flows ever created in a single step, and "not used for training" says nothing about retention, analytics or sub-processors; the consent document does. Second, selection: people who opt into an Apple study skew healthier, wealthier and more digitally literate than the patients who most need reliable health information, so the trust and comprehension findings may not transfer.
What to watch
Enrolment speed, which will show how much appetite there is for a branded health chatbot. The first published results on answer quality and behaviour change, which health systems can use to decide whether to point patients at it. Whether a payer or pharmacy partner follows, which would reveal the business model. And how Apple handles the first widely shared bad answer, because at 200,000 users there will be one.
The story so far
- Nov 17, 2026 macOS 27.3 tightens Full Disk Access because of AI agents: silent denials, no one-click toggle, and a 'Private Folders' …
- Nov 14, 2026 ChatGPT Wallet: network tokens, one biometric approval per purchase and no OpenAI fee at launch. What merchants and secu…
- Nov 13, 2026 63% of US physicians now use AI for clinical decision support, up from 37% a year ago, Doximity's survey of 3,379 doctor…
- Nov 12, 2026 United Airlines wrote AI agents into its contract of carriage as a prohibited practice: what the text says and what reta…
Key terms in this story
- Sub-processor A vendor's own vendor that handles your data on its behalf, such as the inference provider behind a SaaS product's AI feature.
More in Health & medicine
All →
GE HealthCare's Critical Care Suite 3.0 clears the FDA: feeding-tube detection on the x-ray machine at 99.2% sensitivity, offline, and for children for the first time. What hospitals should ask before switching it on
On-device imaging AI sidesteps the integration and data-sharing problems that stall most hospital deployments; the questions that remain are about the…

Isomorphic Labs raises $5 billion with no drug in a human: the largest private biotech round ever, $7.7 billion in twenty months, and what the money is actually buying
The DeepMind spinout has now raised more than most public biotechs are worth, on preclinical data it has not published. The bet is that an AI design e…

AlphaGenome 2: a conditional DNA model trained on 107 million cell profiles finds nearly twice the expression-changing variants. What it does and does not mean for drug discovery
DeepMind's second genome model answers the question the first could not: what a variant does in this cell type. That is the question target-discovery …
Get the brief in your inbox
One email every morning: the stories that mattered in AI, each with a one-line "why it matters" for your role. Free, no ads, unsubscribe any time.
Published daily by AI Briefing. We never share your address.